We’re adding to our position in this out-of-favor, high-quality drugmaker stock

cnbc.com/2025/05/22/were-adding-to-position-in-this-out-of-favor-high-quality-drugmaker.html

With shares trading at a 52-week low and only 24 times its estimated 2026 EPS, many risks have already been priced in.

This story appeared on cnbc.com, 2025-05-22 16:12:05.
The Entire Business World on a Single Page. Free to Use →